Market Research Logo

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2015

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2015’, provides an overview of the Cytomegalovirus (HHV-5) Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cytomegalovirus (HHV-5) Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Cytomegalovirus (HHV-5) Infections Overview
Therapeutics Development
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis
Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies
Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes
Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Cytomegalovirus (HHV-5) Infections - Products under Development by Companies
Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes
Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development
3-V Biosciences, Inc.
AIMM Therapeutics B.V.
AlphaVax, Inc.
Altor BioScience Corporation
Applied Immune Technologies Ltd
Astellas Pharma Inc.
BioApex, s.r.o.
Bionor Pharma ASA
Biotest AG
CAP-CMV GmbH
Cell Medica Limited
Chimerix, Inc.
GlaxoSmithKline plc
Hookipa Biotech AG
Humabs BioMed SA
INAGEN ApS
iQur Ltd.
Kadmon Corporation, LLC
Lead Discovery Center GmbH
Merck & Co., Inc.
Microbiotix, Inc.
Novartis AG
Pfizer Inc.
Phoenix Biotechnology, Inc.
Spider Biotech
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccines Inc.
Vical Incorporated
Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AL-18 - Drug Profile
Antibody to Inhibit HLA-A2 for Cytomegalovirus Infections - Drug Profile
Antiviral TCR-Ck - Drug Profile
Antiviral TCR-Ig - Drug Profile
ASP-0113 - Drug Profile
AVX-601 - Drug Profile
BA-368 - Drug Profile
brincidofovir - Drug Profile
BT-084 - Drug Profile
CAPCMV-001 - Drug Profile
Cell Therapy 3 For CMV - Drug Profile
Cell Therapy for CMV Infections - Drug Profile
Cell Therapy for Cytomegalovirus (HHV-5) Infections - Drug Profile
Cell Therapy for Cytomegalovirus Infections - Drug Profile
Cell Therapy for Cytomegalovirus Infections - Drug Profile
Cell Therapy for Cytomegalovirus Infections and GBM - Drug Profile
Cell Therapy for Infectious Disease - Drug Profile
Cell Therapy for Infectious Diseases - Drug Profile
Cell Therapy to Target PP65 for Cytomegalovirus Infections - Drug Profile
Cell Therapy to Target PP65 for Cytomegalovirus Infections - Drug Profile
CMX-669 - Drug Profile
CSJ-148 - Drug Profile
CyMVectin - Drug Profile
cytomegalovirus (virus like particle) vaccine - Drug Profile
cytomegalovirus vaccine - Drug Profile
cytomegalovirus vaccine - Drug Profile
Cytomegalovirus vaccine - Drug Profile
cytomegalovirus vaccine - Drug Profile
cytomegalovirus vaccine 1 - Drug Profile
Cytovir-CMV - Drug Profile
Dendritic Cell Therapy for Oncology and Infectious Disease - Drug Profile
Dendritic Cell Therapyto Target CMV Antigen for Cytomegalovirus Infections - Drug Profile
Drug for Cytomegalovirus - Drug Profile
filociclovir - Drug Profile
Gene Therapy for Cytomegalovirus Infections - Drug Profile
HB-101 - Drug Profile
LDC-4297 - Drug Profile
letermovir - Drug Profile
maribavir - Drug Profile
MBX-2168 - Drug Profile
Monoclonal Antibody for Cytomegalovirus Infections - Drug Profile
Monoclonal Antibody for HCMV Infections - Drug Profile
Peptides to Inhibit Heparan Sulfate for HHV-5 Infections - Drug Profile
Protein For Cytomegalovirus Infections - Drug Profile
RBT-301 - Drug Profile
Recombinant Peptide for Infectious Diseases - Drug Profile
RKP-00156 - Drug Profile
SB-105A10 - Drug Profile
Small Molecule 1 for Human Cytomegalovirus Infection - Drug Profile
Small Molecule 2 for Human Cytomegalovirus Infection - Drug Profile
Small Molecule 3 for Human Cytomegalovirus Infection - Drug Profile
Small Molecules for CMV Infections - Drug Profile
Small Molecules for Viral Infections - Drug Profile
Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile
Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile
Small Molecules to Inhibit Fatty Acid Synthase for Viral Infections - Drug Profile
TRL-345 - Drug Profile
V-160 - Drug Profile
Vacc-CMV - Drug Profile
VBI-1501A - Drug Profile
Viralym-C - Drug Profile
VPM-2001 - Drug Profile
Cytomegalovirus (HHV-5) Infections - Recent Pipeline Updates
Cytomegalovirus (HHV-5) Infections - Dormant Projects
Cytomegalovirus (HHV-5) Infections - Discontinued Products
Cytomegalovirus (HHV-5) Infections - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2015
Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by 3-V Biosciences, Inc., H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics B.V., H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by AlphaVax, Inc., H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Altor BioScience Corporation, H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Applied Immune Technologies Ltd, H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Astellas Pharma Inc., H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by BioApex, s.r.o., H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Bionor Pharma ASA, H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by CAP-CMV GmbH, H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Cell Medica Limited, H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix, Inc., H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline plc, H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Biotech AG, H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Humabs BioMed SA, H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by INAGEN ApS, H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by iQur Ltd., H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corporation, LLC, H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Lead Discovery Center GmbH, H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co., Inc., H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix, Inc., H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Pfizer Inc., H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology, Inc., H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Spider Biotech, H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience, Inc., H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc., H1 2015
Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Incorporated, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Cytomegalovirus (HHV-5) Infections Therapeutics - Recent Pipeline Updates, H1 2015
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2015
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..1), H1 2015
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..2), H1 2015
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..3), H1 2015
Cytomegalovirus (HHV-5) Infections - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2015
Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report